Pub Date : 2021-02-09DOI: 10.19080/ctoij.2021.18.555978
P. Nagpal, D. Pruthi, P. Shanmugan, Paranthaman Chinnakari, Manish Pandey, Harpreet Singh
Introduction: Head and Neck tumors are mainly treated with concurrent chemoradiation. Treatment delivery with Megavoltage beam has the advantage of skin sparing effect but still skin reactions have been a major side effect since 2D era. Initially these reactions were due to the delivery with bilateral opposed portals but with advent of IMRT/ VMAT, it has been possible to escalate the tumor dose with the need of strict immobilization with thermoplastic mask. This thermoplastic mask may have a bolus effect and can result in increase in surface dose resulting in skin reactions. The aim of this study was to evaluate if any bolus effect of thermoplastic mask exists. Materials and Methods: A total of 15 patients of histologically proven carcinoma oropharynx and hypopharynx were taken. Patients were scanned for planning CT with thermoplastic mask. Another scan was taken in the same position but without thermoplastic mask. Same contouring and planning were done on both the scans. Plans were made and ascertained that all OAR’s and target volumes should get similar doses. Skin contoured on both the scans was evaluated for the dose received. Results: Mean dose received by skin in patients with thermoplastic mask was 48.15 GY while Mean dose received by skin in patients without thermoplastic mask was 43.18 GY. A paired t-test was applied on the dataset which revealed a statistically significant difference between the skin doses with and without mask with a p value of < 0.05. Conclusion: Increase in skin dose can be attributed of the bolus effect of thermoplastic mask. This bolus effect should be considered once high dose to skin is observed during planning or patient develops skin reaction.
{"title":"Does Thermoplastic Mask Alleivates Skin Sparing Effect of Photons in Head and Neck Cancer Patients: A Pilot study","authors":"P. Nagpal, D. Pruthi, P. Shanmugan, Paranthaman Chinnakari, Manish Pandey, Harpreet Singh","doi":"10.19080/ctoij.2021.18.555978","DOIUrl":"https://doi.org/10.19080/ctoij.2021.18.555978","url":null,"abstract":"Introduction: Head and Neck tumors are mainly treated with concurrent chemoradiation. Treatment delivery with Megavoltage beam has the advantage of skin sparing effect but still skin reactions have been a major side effect since 2D era. Initially these reactions were due to the delivery with bilateral opposed portals but with advent of IMRT/ VMAT, it has been possible to escalate the tumor dose with the need of strict immobilization with thermoplastic mask. This thermoplastic mask may have a bolus effect and can result in increase in surface dose resulting in skin reactions. The aim of this study was to evaluate if any bolus effect of thermoplastic mask exists. Materials and Methods: A total of 15 patients of histologically proven carcinoma oropharynx and hypopharynx were taken. Patients were scanned for planning CT with thermoplastic mask. Another scan was taken in the same position but without thermoplastic mask. Same contouring and planning were done on both the scans. Plans were made and ascertained that all OAR’s and target volumes should get similar doses. Skin contoured on both the scans was evaluated for the dose received. Results: Mean dose received by skin in patients with thermoplastic mask was 48.15 GY while Mean dose received by skin in patients without thermoplastic mask was 43.18 GY. A paired t-test was applied on the dataset which revealed a statistically significant difference between the skin doses with and without mask with a p value of < 0.05. Conclusion: Increase in skin dose can be attributed of the bolus effect of thermoplastic mask. This bolus effect should be considered once high dose to skin is observed during planning or patient develops skin reaction.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84147527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-03DOI: 10.19080/ctoij.2021.18.555977
Z. Ali, Morsy Aieat, M. Osama, Hussien Marwa, A. Ebrahim
Objective: Assessment the management of positive cervical lymph nodes in parotid cancer. Associated clinical symptoms, histological types, regional lymph node stage (n stage), occult metastasis, neck dissection by level, recurrence, neck irradiation. Methods. We carried out a retrospective analysis of 43 patient’s pathological positive lymph nodes metastatic from parodied cancer, who underwent neck dissection. treated in years 2010-2020, we analyzed the following parameters: age, sex, pT-Status, tumour size, skin invasion, facial nerve palsy, tumour fixation, extraparotid extension, localization, grade, histology, Distribution of T classification was: T3 (60%), and T4 (40%). Results: Mean patient age was 52 years, the most common location of cervical Nodes Met. was level II (72%), then III (49%) then I (42%), then IV (40%) and V (19%). The incidence was highest among patients with (27.9%) mucoepidermoid carcinoma was most common, followed by (14.6%) carcinoma ex-pleomorphic adenoma (9.3%) with acinic cell carcinoma (7%) with squamous cell carcinoma, (11.6%) with adenoid cystic carcinoma, (7.0%) with adenocarcinoma, (7.4%) salivary duct carcinoma, When classified by histological grade, 35% of patients with low/intermediate-grade versus 65.0% high-grade ., Pre-operative fine needle aspiration (83.7%) patients, Post-surgical irradiation was performed in all 43 patients (100%). The resection status (R) was Negative margins R0. (93%), lymphovascular space invasion (44.2%) and (25.6%) had perineural invasion. Skin invasion in (14%) patients, and (4.7%) had regional nodal recurrence (7%) patients with pN1, vs (93%) patients with pN2. Pathologically positive lymph node 4 (range: 1–8 Nodes) lymph nodes harvest 29(range, 23–41 lymph nodes)., Conclusion: modified Radical Neck Dissection with additional radiotherapy should be carried out in patients. Nodes positive parotied cancer especially High histological stage, advanced stage, perineural invasion, positive operative edge, a fixed mass with extra parotid extension facial-nerve paralysis and tumor pain in partied cancer.
{"title":"Management of Positive Cervical Lymph Nodes in Parotid Cancer","authors":"Z. Ali, Morsy Aieat, M. Osama, Hussien Marwa, A. Ebrahim","doi":"10.19080/ctoij.2021.18.555977","DOIUrl":"https://doi.org/10.19080/ctoij.2021.18.555977","url":null,"abstract":"Objective: Assessment the management of positive cervical lymph nodes in parotid cancer. Associated clinical symptoms, histological types, regional lymph node stage (n stage), occult metastasis, neck dissection by level, recurrence, neck irradiation. Methods. We carried out a retrospective analysis of 43 patient’s pathological positive lymph nodes metastatic from parodied cancer, who underwent neck dissection. treated in years 2010-2020, we analyzed the following parameters: age, sex, pT-Status, tumour size, skin invasion, facial nerve palsy, tumour fixation, extraparotid extension, localization, grade, histology, Distribution of T classification was: T3 (60%), and T4 (40%). Results: Mean patient age was 52 years, the most common location of cervical Nodes Met. was level II (72%), then III (49%) then I (42%), then IV (40%) and V (19%). The incidence was highest among patients with (27.9%) mucoepidermoid carcinoma was most common, followed by (14.6%) carcinoma ex-pleomorphic adenoma (9.3%) with acinic cell carcinoma (7%) with squamous cell carcinoma, (11.6%) with adenoid cystic carcinoma, (7.0%) with adenocarcinoma, (7.4%) salivary duct carcinoma, When classified by histological grade, 35% of patients with low/intermediate-grade versus 65.0% high-grade ., Pre-operative fine needle aspiration (83.7%) patients, Post-surgical irradiation was performed in all 43 patients (100%). The resection status (R) was Negative margins R0. (93%), lymphovascular space invasion (44.2%) and (25.6%) had perineural invasion. Skin invasion in (14%) patients, and (4.7%) had regional nodal recurrence (7%) patients with pN1, vs (93%) patients with pN2. Pathologically positive lymph node 4 (range: 1–8 Nodes) lymph nodes harvest 29(range, 23–41 lymph nodes)., Conclusion: modified Radical Neck Dissection with additional radiotherapy should be carried out in patients. Nodes positive parotied cancer especially High histological stage, advanced stage, perineural invasion, positive operative edge, a fixed mass with extra parotid extension facial-nerve paralysis and tumor pain in partied cancer.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75166480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-29DOI: 10.19080/CTOIJ.2021.18.555976
R. Fatima, Hadia Fatima
Background: Limited research has been performed for treating gynecological disease conditions using paleodiet intervention. It is in demand to conduct many randomized controlled trials to prove its effectiveness. This review indicates one of the most important literature gaps in gynae-oncology. Paleo nutrition has recently emerged as a treatment option in conditions related to gynecology, and such potential benefits are indicated in few short-term clinical trials and case reports related to gynecological cancers and malignancies. Objective: This meta-analysis is aimed to address the importance of nutritional intervention, with emphasis on paleo nutrition, in treatment of gynecological cancers, pre-malignancy conditions, and post-operative recovery in women. Materials: PubMed, Scopus, SciPubs, Mayo Clinic, Cochrane Library, Covance Laboratory and ASRM databases were used for collecting data in the form of case reports, research articles, reviews, clinical trials, journals, and books. Design: Out of 400 publications, 7 are shortlisted for their relevance to gynecological oncology and paleo nutrition interventions. Case reports and short-term clinical trials between year 2000-2020 are included for comparative analysis of Paleodiet and its variants with other nutritional interventions. Results: There is no scientific data that has been reported on genetic and molecular impacts of paleo-nutrition on gynecological cancers. Clinical reports suggest significant improvement through paleodiet intervention in anthropometric markers and metabolism in pre-treatment and post-treatment examination of patients of gynae-oncology. Very limited data is available for comparative analysis of paleodiet and other dietary interventions. Conclusion: Paleo nutrition is an under-researched future intervention and has a potential to impact treatment strategies for gynecological patients. A large volume of randomized controlled trials for each ethnic group can help manage the cancer burden globally.
{"title":"Review: Potential Effectiveness of Paleolithic Nutritional Interventions in Treatment of Gynecological Cancers","authors":"R. Fatima, Hadia Fatima","doi":"10.19080/CTOIJ.2021.18.555976","DOIUrl":"https://doi.org/10.19080/CTOIJ.2021.18.555976","url":null,"abstract":"Background: Limited research has been performed for treating gynecological disease conditions using paleodiet intervention. It is in demand to conduct many randomized controlled trials to prove its effectiveness. This review indicates one of the most important literature gaps in gynae-oncology. Paleo nutrition has recently emerged as a treatment option in conditions related to gynecology, and such potential benefits are indicated in few short-term clinical trials and case reports related to gynecological cancers and malignancies. Objective: This meta-analysis is aimed to address the importance of nutritional intervention, with emphasis on paleo nutrition, in treatment of gynecological cancers, pre-malignancy conditions, and post-operative recovery in women. Materials: PubMed, Scopus, SciPubs, Mayo Clinic, Cochrane Library, Covance Laboratory and ASRM databases were used for collecting data in the form of case reports, research articles, reviews, clinical trials, journals, and books. Design: Out of 400 publications, 7 are shortlisted for their relevance to gynecological oncology and paleo nutrition interventions. Case reports and short-term clinical trials between year 2000-2020 are included for comparative analysis of Paleodiet and its variants with other nutritional interventions. Results: There is no scientific data that has been reported on genetic and molecular impacts of paleo-nutrition on gynecological cancers. Clinical reports suggest significant improvement through paleodiet intervention in anthropometric markers and metabolism in pre-treatment and post-treatment examination of patients of gynae-oncology. Very limited data is available for comparative analysis of paleodiet and other dietary interventions. Conclusion: Paleo nutrition is an under-researched future intervention and has a potential to impact treatment strategies for gynecological patients. A large volume of randomized controlled trials for each ethnic group can help manage the cancer burden globally.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"95 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80758624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-29DOI: 10.19080/ctoij.2021.17.555975
Prem Ravi Varma P K
Hepatocellular carcinoma (HCC) remains a highly complex disease resistant to commonly used chemotherapy and radiotherapy. As the fifth most common cancer worldwide with the third highest mortality rate and very poorly understood molecular pathways driving hepatocarcinogenesis, new treatment strategies are urgently needed for this devastating disease. The multi kinase inhibitor Sorafenib was the first molecular targeted drug in HCC that led to significant survival benefit in patients with advanced tumors. It is the first drug to be considered standard of care for advanced HCC and supports the importance of molecular therapies in the treatment of this cancer. Analysis of genetic and epigenetic alterations as well as different molecular pathways involved in the development of HCC help to identify potential new druggable targets. A variety of novel compounds are already under preclinical or clinical investigation, and accumulating evidence suggests that combination therapy targeting different pathways will potentiate anti-tumoral effects and will become the future therapeutic approach. In addition, the establishment of a robust molecular classification will pave the way for a more personalized treatment scheme in HCC. In this article a review of the current knowledge of the molecular pathogenesis of HCC and an overview of molecular targeted therapies in the management of HCC are provided.
{"title":"Oncopharmacogenomics of Hepatocellular Carcinoma - A Therapy Related Review","authors":"Prem Ravi Varma P K","doi":"10.19080/ctoij.2021.17.555975","DOIUrl":"https://doi.org/10.19080/ctoij.2021.17.555975","url":null,"abstract":"Hepatocellular carcinoma (HCC) remains a highly complex disease resistant to commonly used chemotherapy and radiotherapy. As the fifth most common cancer worldwide with the third highest mortality rate and very poorly understood molecular pathways driving hepatocarcinogenesis, new treatment strategies are urgently needed for this devastating disease. The multi kinase inhibitor Sorafenib was the first molecular targeted drug in HCC that led to significant survival benefit in patients with advanced tumors. It is the first drug to be considered standard of care for advanced HCC and supports the importance of molecular therapies in the treatment of this cancer. Analysis of genetic and epigenetic alterations as well as different molecular pathways involved in the development of HCC help to identify potential new druggable targets. A variety of novel compounds are already under preclinical or clinical investigation, and accumulating evidence suggests that combination therapy targeting different pathways will potentiate anti-tumoral effects and will become the future therapeutic approach. In addition, the establishment of a robust molecular classification will pave the way for a more personalized treatment scheme in HCC. In this article a review of the current knowledge of the molecular pathogenesis of HCC and an overview of molecular targeted therapies in the management of HCC are provided.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85364087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-25DOI: 10.19080/CTOIJ.2021.17.555974
I. Kiladze
The optimal treatment of patients with stage IIIA non-small cell lung cancer (NSCLC) remains highly controversial. In resectable stage IIIA NSCLC, there is still a considerable debate regarding the best strategy. Treatment choice is often a function of institutional and/or physician preference. Treatment consists of neo-adjuvant chemotherapy or chemoradiotherapy (CHRT) followed by surgery with or without postoperative radiotherapy (RT), definitive CHRT, or neoadjuvant immunotherapy followed by surgery and several other options. Neo-adjuvant therapy for operable NSCLC has been the subject of a large number of studies in the literature. We summarized existing data and also highlight ongoing trials, focusing on neoadjuvant immunotherapy. Neoadjuvant CHRT seems to be safe and efficient and is associated with an improved pathological outcome, but it has failed to demonstrate any advantage in terms of progression-free survival or overall survival compared to neoadjuvant chemotherapy. Contrary to previous fears, radiotherapy does not add a higher toxicity, nor does it increase post-operative mortality compared to chemotherapy alone. Studies with chemoimmunotherapy provide a higher rate of pathologic responses and downstaging compared to chemotherapy. On the other hand, it remains to be confirmed whether pCR is a sufficient surrogate for OS. Results of ongoing neoadjuvant immunotherapy trials are awaiting and we believe, the next decades will bring much needed improvements for patients. Still the controversy is not being solved and further trials considering a better patients’ selection, innovative radiotherapy and more efficient systemic treatments need to be undertaken.
{"title":"Neoadjuvant Treatment for Resectable, Stage IIIA Non-Small Cell Lung Cancer","authors":"I. Kiladze","doi":"10.19080/CTOIJ.2021.17.555974","DOIUrl":"https://doi.org/10.19080/CTOIJ.2021.17.555974","url":null,"abstract":"The optimal treatment of patients with stage IIIA non-small cell lung cancer (NSCLC) remains highly controversial. In resectable stage IIIA NSCLC, there is still a considerable debate regarding the best strategy. Treatment choice is often a function of institutional and/or physician preference. Treatment consists of neo-adjuvant chemotherapy or chemoradiotherapy (CHRT) followed by surgery with or without postoperative radiotherapy (RT), definitive CHRT, or neoadjuvant immunotherapy followed by surgery and several other options. Neo-adjuvant therapy for operable NSCLC has been the subject of a large number of studies in the literature. We summarized existing data and also highlight ongoing trials, focusing on neoadjuvant immunotherapy. Neoadjuvant CHRT seems to be safe and efficient and is associated with an improved pathological outcome, but it has failed to demonstrate any advantage in terms of progression-free survival or overall survival compared to neoadjuvant chemotherapy. Contrary to previous fears, radiotherapy does not add a higher toxicity, nor does it increase post-operative mortality compared to chemotherapy alone. Studies with chemoimmunotherapy provide a higher rate of pathologic responses and downstaging compared to chemotherapy. On the other hand, it remains to be confirmed whether pCR is a sufficient surrogate for OS. Results of ongoing neoadjuvant immunotherapy trials are awaiting and we believe, the next decades will bring much needed improvements for patients. Still the controversy is not being solved and further trials considering a better patients’ selection, innovative radiotherapy and more efficient systemic treatments need to be undertaken.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86878189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-22DOI: 10.19080/ctoij.2020.17.555972
A. Hunis
Prostate cancer is the second most frequent tumor in men in Argentina. Since the work of Charles Huggins, in 1941, in which he demonstrates that the suppression of the male sex hormone-testosterone-through surgical castration, many years have passed and many advances have been made in terms of diagnosis and treatment of this disease, paradigm of a hormone-dependent tumor. In this work, we intend to summarize the advances and the problems of the disease in the Argentine Republic. in
{"title":"Prostate Cancer, Update of its Diagnosis and Treatment, with Special Emphasis on its Management in Argentina","authors":"A. Hunis","doi":"10.19080/ctoij.2020.17.555972","DOIUrl":"https://doi.org/10.19080/ctoij.2020.17.555972","url":null,"abstract":"Prostate cancer is the second most frequent tumor in men in Argentina. Since the work of Charles Huggins, in 1941, in which he demonstrates that the suppression of the male sex hormone-testosterone-through surgical castration, many years have passed and many advances have been made in terms of diagnosis and treatment of this disease, paradigm of a hormone-dependent tumor. In this work, we intend to summarize the advances and the problems of the disease in the Argentine Republic. in","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83393635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-16DOI: 10.19080/ctoij.2020.17.555971
Anu Bajaj
Mesenchymal soft tissue adipocytic neoplasms are frequently discerned tumors demonstrating diverse histological subcategories. Chondroid lipoma is an extremely exceptional, benign adipocytic neoplasm initially scripted by Meis and Enzinger in 1993 as a tumefaction simulating liposarcoma or myxoid chondrosarcoma [1]. As the neoplasm is composed of mature adipocytes, lipoblasts and myxochondroid stroma, chondroid lipoma may be histologically misinterpreted as an adipose tissue sarcoma, round cell liposarcoma or extra-skeletal myxoid chondrosarcoma. As malignant tumours are therapeutically managed with adjuvant radiotherapy, chemotherapy, and extensive surgical resection wherein benign tumours are appropriately addressed by marginal resection, cogent distinction between benign lipomatous neoplasms from diverse malignant neoplasms is necessitated to circumvent unnecessary therapeutic intervention and associated adverse outcomes. The essentially benign chondroid lipoma does not mandate expansive surgical extermination, adjunctive radiotherapy, or chemotherapy.
{"title":"The Adipocerous Ossein- Chondroid Lipoma","authors":"Anu Bajaj","doi":"10.19080/ctoij.2020.17.555971","DOIUrl":"https://doi.org/10.19080/ctoij.2020.17.555971","url":null,"abstract":"Mesenchymal soft tissue adipocytic neoplasms are frequently discerned tumors demonstrating diverse histological subcategories. Chondroid lipoma is an extremely exceptional, benign adipocytic neoplasm initially scripted by Meis and Enzinger in 1993 as a tumefaction simulating liposarcoma or myxoid chondrosarcoma [1]. As the neoplasm is composed of mature adipocytes, lipoblasts and myxochondroid stroma, chondroid lipoma may be histologically misinterpreted as an adipose tissue sarcoma, round cell liposarcoma or extra-skeletal myxoid chondrosarcoma. As malignant tumours are therapeutically managed with adjuvant radiotherapy, chemotherapy, and extensive surgical resection wherein benign tumours are appropriately addressed by marginal resection, cogent distinction between benign lipomatous neoplasms from diverse malignant neoplasms is necessitated to circumvent unnecessary therapeutic intervention and associated adverse outcomes. The essentially benign chondroid lipoma does not mandate expansive surgical extermination, adjunctive radiotherapy, or chemotherapy.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74995493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-16DOI: 10.19080/ctoij.2020.17.555969
N. Hamed
Which transplant procedure should be delayed during COVID-19 outbreak is a difficult decision due to the variable situation between transplant centers. In general, non-urgent transplants especially those for non-malignant disorders should be deferred as much as possible. Appropriate local advice and support groups are of paramount importance for those who will have treatment delay. Patients might suffer harm if necessary, transplants are delayed due to COVID-19 infection. Patients having undergone SCT require specific guidance and policies. An important issue is deferral of transplant candidates if they become COVID-19 infected.
{"title":"Challenges during Bone Marrow Transplantation in COVID-19 era","authors":"N. Hamed","doi":"10.19080/ctoij.2020.17.555969","DOIUrl":"https://doi.org/10.19080/ctoij.2020.17.555969","url":null,"abstract":"Which transplant procedure should be delayed during COVID-19 outbreak is a difficult decision due to the variable situation between transplant centers. In general, non-urgent transplants especially those for non-malignant disorders should be deferred as much as possible. Appropriate local advice and support groups are of paramount importance for those who will have treatment delay. Patients might suffer harm if necessary, transplants are delayed due to COVID-19 infection. Patients having undergone SCT require specific guidance and policies. An important issue is deferral of transplant candidates if they become COVID-19 infected.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"2 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91463073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-15DOI: 10.19080/ctoij.2020.17.555968
Manoj Kumar Suman
Purpose: In Indian scenario Head and neck cancer is the second most cancer. As compared to female it is more common in male. In radiotherapy, conventional fractionation (5Fx/week) and accelerated fractionation (6fx/week) is being advocated. Squamous cell carcinoma of the Head and neck cancer is predominantly a loco regional disease. The objective of the present study is comparison between conventional v/s accelerated fractions of radiotherapy in Squamous cell carcinoma of locally advanced Head and neck cancer. Methods: This prospective randomized single Institutional study done from July 2018 to November 2019 at Mathura Das Mathur Hospital, Jodhpur has compared the accelerated fractionation (66 Gy/33#, 6 days per week) with conventional fractionation (66 Gy/33 #, 5 days per week) in Squamous cell carcinoma of Head and neck patients. Comparison was done between the two radiotherapy schedules comprising of 25 patients each Arm. Results and Conclusion: The rate of grade I and II toxicities were similar in both arms. In the present study has proved that accelerated fraction provide benefit mainly by local tumor control. The rates of grade III toxicities were significantly more in accelerated arm. So, when selecting the patients for these regimes’ institutional workload, disease status and patients related factors should be considered.
目的:在印度，头颈癌是第二大癌症。与女性相比，男性更常见。在放疗中，提倡常规分割(5Fx/周)和加速分割(6fx/周)。头颈部鳞状细胞癌主要是一种局部区域性疾病。本研究的目的是比较传统的v/s加速部分放疗在局部晚期头颈癌鳞状细胞癌中的作用。方法:这项前瞻性随机单机构研究于2018年7月至2019年11月在Jodhpur的Mathura Das Mathur医院进行，比较了头颈部鳞状细胞癌患者的加速分离(66 Gy/33#，每周6天)和常规分离(66 Gy/33#，每周5天)。比较两组放疗方案，每组25例患者。结果与结论:两组ⅰ级和ⅱ级毒性发生率相似。目前的研究证明，加速剂主要通过局部肿瘤控制来提供益处。III级毒性发生率在加速组明显更高。因此，在为这些制度的机构工作量选择患者时，应考虑疾病状况和患者相关因素。
{"title":"Comparison of Conventional versus Accelerated Fractions of Radiotherapy per Week for Squamous Cell Carcinoma of the Head and Neck","authors":"Manoj Kumar Suman","doi":"10.19080/ctoij.2020.17.555968","DOIUrl":"https://doi.org/10.19080/ctoij.2020.17.555968","url":null,"abstract":"Purpose: In Indian scenario Head and neck cancer is the second most cancer. As compared to female it is more common in male. In radiotherapy, conventional fractionation (5Fx/week) and accelerated fractionation (6fx/week) is being advocated. Squamous cell carcinoma of the Head and neck cancer is predominantly a loco regional disease. The objective of the present study is comparison between conventional v/s accelerated fractions of radiotherapy in Squamous cell carcinoma of locally advanced Head and neck cancer. Methods: This prospective randomized single Institutional study done from July 2018 to November 2019 at Mathura Das Mathur Hospital, Jodhpur has compared the accelerated fractionation (66 Gy/33#, 6 days per week) with conventional fractionation (66 Gy/33 #, 5 days per week) in Squamous cell carcinoma of Head and neck patients. Comparison was done between the two radiotherapy schedules comprising of 25 patients each Arm. Results and Conclusion: The rate of grade I and II toxicities were similar in both arms. In the present study has proved that accelerated fraction provide benefit mainly by local tumor control. The rates of grade III toxicities were significantly more in accelerated arm. So, when selecting the patients for these regimes’ institutional workload, disease status and patients related factors should be considered.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"90 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78407415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-14DOI: 10.19080/ctoij.2020.17.555967
R. Das
Cancer and diabetes mellitus (DM) are frequently occurring diseases with frightening impact on human health worldwide. In epidemiological studies, it is observed that people with DM are always at higher risk for several types of cancer [1-4]. Some research reports have pointed that there is a direct link between overweight and cruelty of breast cancer (BC) [5-7]. Correlation between the BC prognosis and metabolic syndrome has been reported in [8]. The following inquiries are surveyed in the present editorial report.
{"title":"Role of Glucose on Breast Cancer Patients","authors":"R. Das","doi":"10.19080/ctoij.2020.17.555967","DOIUrl":"https://doi.org/10.19080/ctoij.2020.17.555967","url":null,"abstract":"Cancer and diabetes mellitus (DM) are frequently occurring diseases with frightening impact on human health worldwide. In epidemiological studies, it is observed that people with DM are always at higher risk for several types of cancer [1-4]. Some research reports have pointed that there is a direct link between overweight and cruelty of breast cancer (BC) [5-7]. Correlation between the BC prognosis and metabolic syndrome has been reported in [8]. The following inquiries are surveyed in the present editorial report.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89866586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：